BIIB
Income statement / Annual
Last year (2023), Biogen Inc.'s total revenue was $9.84 B,
a decrease of 3.32% from the previous year.
In 2023, Biogen Inc.'s net income was $1.16 B.
See Biogen Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$9.84 B
|
$10.17 B
|
$10.98 B
|
$13.44 B
|
$14.38 B
|
$13.45 B
|
$12.27 B
|
$11.45 B
|
$10.76 B
|
$9.70 B
|
| Cost of Revenue |
$2.53 B |
$2.28 B |
$2.11 B |
$1.81 B |
$1.96 B |
$1.82 B |
$1.63 B |
$1.48 B |
$1.24 B |
$1.17 B |
| Gross Profit |
$7.30 B |
$7.90 B |
$8.87 B |
$11.64 B |
$12.42 B |
$11.64 B |
$10.64 B |
$9.97 B |
$9.52 B |
$8.53 B |
| Gross Profit Ratio |
0.74 |
0.78 |
0.81 |
0.87 |
0.86 |
0.86 |
0.87 |
0.87 |
0.88 |
0.88 |
| Research and Development
Expenses |
$2.46 B
|
$2.23 B
|
$2.50 B
|
$3.99 B
|
$2.28 B
|
$2.60 B
|
$2.25 B
|
$1.97 B
|
$2.01 B
|
$1.89 B
|
| General & Administrative
Expenses |
$2.48 B
|
$2.35 B
|
$2.58 B
|
$2.39 B
|
$2.30 B
|
$2.02 B
|
$1.86 B
|
$1.84 B
|
$2.00 B
|
$2.14 B
|
| Selling & Marketing
Expenses |
$71.40 M
|
$54.10 M
|
$98.70 M
|
$111.80 M
|
$79.20 M
|
$90.20 M
|
$75.20 M
|
$106.30 M
|
$108.60 M
|
$92.90 M
|
| Selling, General &
Administrative Expenses |
$2.55 B
|
$2.40 B
|
$2.67 B
|
$2.50 B
|
$2.37 B
|
$2.11 B
|
$1.94 B
|
$1.95 B
|
$2.11 B
|
$2.23 B
|
| Other Expenses |
-$3.50 M |
$358.50 M |
$888.50 M |
$697.70 M |
$731.50 M |
$11.00 M |
-$215.40 M |
-$217.40 M |
-$123.70 M |
-$25.78 M |
| Operating Expenses |
$5.47 B |
$4.99 B |
$6.06 B |
$7.19 B |
$5.39 B |
$5.64 B |
$5.12 B |
$4.32 B |
$4.51 B |
$4.62 B |
| Cost And Expenses |
$8.00 B |
$7.27 B |
$8.17 B |
$9.00 B |
$7.34 B |
$7.45 B |
$6.75 B |
$5.80 B |
$5.75 B |
$5.79 B |
| Interest Income |
$276.50 M |
$89.30 M |
$11.00 M |
$42.00 M |
$120.00 M |
$112.50 M |
$78.50 M |
$63.40 M |
$22.10 M |
$12.20 M |
| Interest Expense |
$246.90 M |
$246.60 M |
$253.60 M |
$222.50 M |
$187.40 M |
$200.60 M |
$250.80 M |
$260.00 M |
$95.50 M |
$29.50 M |
| Depreciation &
Amortization |
$494.80 M
|
$518.70 M
|
$487.30 M
|
$457.00 M
|
$464.60 M
|
$650.60 M
|
$721.60 M
|
$682.70 M
|
$382.60 M
|
$489.76 M
|
| EBITDA |
$2.60 B
|
$2.69 B
|
$3.66 B
|
$4.81 B
|
$7.52 B
|
$6.86 B
|
$6.53 B
|
$6.54 B
|
$5.52 B
|
$4.35 B
|
| EBITDA Ratio |
0.26 |
0.26 |
0.33 |
0.36 |
0.52 |
0.51 |
0.53 |
0.57 |
0.51 |
0.45 |
| Operating Income Ratio
|
0.13
|
0.23
|
0.26
|
0.34
|
0.49
|
0.44
|
0.44
|
0.45
|
0.45
|
0.41
|
| Total Other
Income/Expenses Net |
-$563.90 M
|
$1.27 B
|
-$1.10 B
|
$497.40 M
|
$83.30 M
|
-$101.20 M
|
-$399.00 M
|
-$720.10 M
|
-$247.60 M
|
$29.87 M
|
| Income Before Tax |
$1.30 B |
$3.59 B |
$1.75 B |
$5.05 B |
$7.13 B |
$5.90 B |
$5.13 B |
$4.93 B |
$4.77 B |
$3.95 B |
| Income Before Tax Ratio
|
0.13
|
0.35
|
0.16
|
0.38
|
0.5
|
0.44
|
0.42
|
0.43
|
0.44
|
0.41
|
| Income Tax Expense |
$135.30 M |
$632.80 M |
$52.50 M |
$992.30 M |
$1.16 B |
$1.43 B |
$2.46 B |
$1.24 B |
$1.16 B |
$989.94 M |
| Net Income |
$1.16 B |
$3.05 B |
$1.56 B |
$4.00 B |
$5.89 B |
$4.43 B |
$2.54 B |
$3.70 B |
$3.55 B |
$2.93 B |
| Net Income Ratio |
0.12 |
0.3 |
0.14 |
0.3 |
0.41 |
0.33 |
0.21 |
0.32 |
0.33 |
0.3 |
| EPS |
8.02 |
20.97 |
10.44 |
24.86 |
31.47 |
21.62 |
11.94 |
16.96 |
15.38 |
12.42 |
| EPS Diluted |
7.97 |
20.87 |
10.4 |
24.8 |
31.42 |
21.58 |
11.92 |
16.93 |
15.34 |
12.37 |
| Weighted Average Shares
Out |
$144.70 M
|
$145.30 M
|
$149.10 M
|
$160.90 M
|
$187.10 M
|
$204.90 M
|
$212.60 M
|
$218.40 M
|
$230.70 M
|
$236.36 M
|
| Weighted Average Shares
Out Diluted |
$145.60 M
|
$146.00 M
|
$149.60 M
|
$161.30 M
|
$187.40 M
|
$205.30 M
|
$213.00 M
|
$218.80 M
|
$231.20 M
|
$237.18 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
